{
  "_metadata": {
    "version": "1.0.0",
    "lastUpdated": "2026-02-06",
    "description": "Central medication database for Neuro Plans - single source of truth for all medication data",
    "safetyNotice": "This database is for clinical decision support only. Always verify dosing against current prescribing information and institutional protocols.",
    "schema": {
      "medication": {
        "id": "Unique identifier (lowercase, hyphenated)",
        "name": "Display name",
        "genericName": "Generic/INN name",
        "brandNames": ["Array of brand names"],
        "drugClass": "Pharmacological class",
        "mechanisms": ["Mechanism(s) of action"],
        "routes": ["Available routes"],
        "formulations": ["Available formulations"],
        "contexts": {
          "[indication-id]": {
            "indication": "Specific use case",
            "doseOptions": [{"text": "", "orderSentence": ""}],
            "startingDose": "Recommended starting dose",
            "maxDose": "Maximum dose for this indication",
            "titration": "Titration schedule",
            "notes": "Indication-specific notes"
          }
        },
        "safety": {
          "blackBoxWarnings": ["FDA black box warnings"],
          "contraindications": ["Absolute contraindications"],
          "precautions": ["Warnings and precautions"],
          "drugInteractions": [{"drug": "", "severity": "", "effect": ""}],
          "pregnancyCategory": "FDA pregnancy category",
          "lactation": "Lactation safety"
        },
        "renalAdjustment": {
          "required": true,
          "tiers": [
            {"gfr": "≥60", "adjustment": "No adjustment"},
            {"gfr": "30-59", "adjustment": "Specific adjustment"},
            {"gfr": "15-29", "adjustment": "Specific adjustment"},
            {"gfr": "<15", "adjustment": "Specific adjustment"},
            {"gfr": "HD", "adjustment": "Hemodialysis dosing"}
          ]
        },
        "hepaticAdjustment": {
          "required": false,
          "notes": "Child-Pugh based adjustments if applicable"
        },
        "monitoring": {
          "baseline": ["Required baseline labs/tests"],
          "ongoing": ["Ongoing monitoring requirements"],
          "frequency": "Monitoring frequency"
        },
        "patientCounseling": ["Key counseling points"]
      }
    }
  },
  "medications": {
    "gabapentin": {
      "id": "gabapentin",
      "name": "Gabapentin",
      "genericName": "gabapentin",
      "brandNames": ["Neurontin", "Gralise", "Horizant"],
      "drugClass": "Gabapentinoid / Anticonvulsant",
      "mechanisms": ["Binds alpha-2-delta subunit of voltage-gated calcium channels", "Reduces excitatory neurotransmitter release"],
      "routes": ["PO"],
      "formulations": ["100 mg capsule", "300 mg capsule", "400 mg capsule", "600 mg tablet", "800 mg tablet", "250 mg/5mL solution"],
      "contexts": {
        "neuropathic-pain": {
          "indication": "Neuropathic pain (diabetic neuropathy, post-herpetic neuralgia, small fiber neuropathy)",
          "doseOptions": [
            {"text": "100 mg TID", "orderSentence": "Gabapentin 100 mg PO TID"},
            {"text": "300 mg TID", "orderSentence": "Gabapentin 300 mg PO TID"},
            {"text": "600 mg TID", "orderSentence": "Gabapentin 600 mg PO TID"},
            {"text": "900 mg TID", "orderSentence": "Gabapentin 900 mg PO TID"},
            {"text": "1200 mg TID", "orderSentence": "Gabapentin 1200 mg PO TID"}
          ],
          "startingDose": "300 mg QHS or 100-300 mg TID",
          "maxDose": "3600 mg/day",
          "titration": "Increase by 300 mg every 1-3 days as tolerated",
          "notes": "First-line for neuropathic pain; full effect may take 2-4 weeks"
        },
        "epilepsy": {
          "indication": "Adjunctive therapy for partial seizures",
          "doseOptions": [
            {"text": "300 mg TID", "orderSentence": "Gabapentin 300 mg PO TID"},
            {"text": "400 mg TID", "orderSentence": "Gabapentin 400 mg PO TID"},
            {"text": "600 mg TID", "orderSentence": "Gabapentin 600 mg PO TID"},
            {"text": "800 mg TID", "orderSentence": "Gabapentin 800 mg PO TID"},
            {"text": "1200 mg TID", "orderSentence": "Gabapentin 1200 mg PO TID"}
          ],
          "startingDose": "300 mg TID",
          "maxDose": "3600 mg/day",
          "titration": "Increase by 300 mg every 1-3 days",
          "notes": "Adjunctive only; monotherapy not FDA-approved for epilepsy"
        },
        "tremor": {
          "indication": "Essential tremor",
          "doseOptions": [
            {"text": "300 mg TID", "orderSentence": "Gabapentin 300 mg PO TID"},
            {"text": "400 mg TID", "orderSentence": "Gabapentin 400 mg PO TID"},
            {"text": "600 mg TID", "orderSentence": "Gabapentin 600 mg PO TID"}
          ],
          "startingDose": "300 mg TID",
          "maxDose": "1800 mg/day",
          "titration": "Increase weekly as tolerated",
          "notes": "Second-line after propranolol/primidone; limited evidence"
        },
        "migraine-prophylaxis": {
          "indication": "Migraine prophylaxis",
          "doseOptions": [
            {"text": "300 mg QHS", "orderSentence": "Gabapentin 300 mg PO QHS"},
            {"text": "300 mg BID", "orderSentence": "Gabapentin 300 mg PO BID"},
            {"text": "400 mg TID", "orderSentence": "Gabapentin 400 mg PO TID"},
            {"text": "600 mg TID", "orderSentence": "Gabapentin 600 mg PO TID"}
          ],
          "startingDose": "300 mg QHS",
          "maxDose": "2400 mg/day",
          "titration": "Increase every 1-2 weeks",
          "notes": "Off-label; moderate evidence; may help with sleep"
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": ["Known hypersensitivity to gabapentin"],
        "precautions": [
          "Respiratory depression risk when combined with CNS depressants or opioids",
          "Suicidal ideation (class warning for antiepileptics)",
          "Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)",
          "Dizziness and somnolence - fall risk in elderly",
          "Abuse potential (Schedule V in some states)"
        ],
        "drugInteractions": [
          {"drug": "Opioids", "severity": "high", "effect": "Increased respiratory depression risk"},
          {"drug": "CNS depressants", "severity": "moderate", "effect": "Additive sedation"},
          {"drug": "Antacids", "severity": "low", "effect": "Reduced gabapentin absorption - separate by 2 hours"}
        ],
        "pregnancyCategory": "C",
        "lactation": "Compatible with breastfeeding (low levels in milk)"
      },
      "renalAdjustment": {
        "required": true,
        "tiers": [
          {"gfr": "≥60", "adjustment": "No adjustment needed (max 3600 mg/day)"},
          {"gfr": "30-59", "adjustment": "Max 900-1400 mg/day in divided doses"},
          {"gfr": "15-29", "adjustment": "Max 300-600 mg/day"},
          {"gfr": "<15", "adjustment": "Max 100-300 mg/day"},
          {"gfr": "HD", "adjustment": "125-350 mg after each dialysis session"}
        ]
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": "No adjustment needed - not hepatically metabolized"
      },
      "monitoring": {
        "baseline": ["Renal function (BMP/CrCl)"],
        "ongoing": ["Renal function periodically", "Suicidal ideation", "Sedation/dizziness"],
        "frequency": "Renal function annually or more often if changing"
      },
      "patientCounseling": [
        "Do not stop abruptly - taper over 1 week minimum to avoid withdrawal/seizures",
        "May cause drowsiness - avoid driving until effects known",
        "Takes 2-4 weeks to reach full effect for pain",
        "Take with or without food",
        "Report mood changes, suicidal thoughts, or rash immediately"
      ]
    },
    "pregabalin": {
      "id": "pregabalin",
      "name": "Pregabalin",
      "genericName": "pregabalin",
      "brandNames": ["Lyrica", "Lyrica CR"],
      "drugClass": "Gabapentinoid / Anticonvulsant",
      "mechanisms": ["Binds alpha-2-delta subunit of voltage-gated calcium channels", "Reduces excitatory neurotransmitter release"],
      "routes": ["PO"],
      "formulations": ["25 mg capsule", "50 mg capsule", "75 mg capsule", "100 mg capsule", "150 mg capsule", "200 mg capsule", "225 mg capsule", "300 mg capsule"],
      "contexts": {
        "neuropathic-pain": {
          "indication": "Neuropathic pain (diabetic neuropathy, post-herpetic neuralgia, small fiber neuropathy)",
          "doseOptions": [
            {"text": "50 mg TID", "orderSentence": "Pregabalin 50 mg PO TID"},
            {"text": "75 mg BID", "orderSentence": "Pregabalin 75 mg PO BID"},
            {"text": "100 mg TID", "orderSentence": "Pregabalin 100 mg PO TID"},
            {"text": "150 mg BID", "orderSentence": "Pregabalin 150 mg PO BID"},
            {"text": "200 mg BID", "orderSentence": "Pregabalin 200 mg PO BID"},
            {"text": "300 mg BID", "orderSentence": "Pregabalin 300 mg PO BID"}
          ],
          "startingDose": "75 mg BID or 50 mg TID",
          "maxDose": "600 mg/day",
          "titration": "May increase to 150 mg BID after 1 week, then to 300 mg BID after another week",
          "notes": "First-line for neuropathic pain; faster onset than gabapentin"
        },
        "fibromyalgia": {
          "indication": "Fibromyalgia",
          "doseOptions": [
            {"text": "75 mg BID", "orderSentence": "Pregabalin 75 mg PO BID"},
            {"text": "150 mg BID", "orderSentence": "Pregabalin 150 mg PO BID"},
            {"text": "225 mg BID", "orderSentence": "Pregabalin 225 mg PO BID"}
          ],
          "startingDose": "75 mg BID",
          "maxDose": "450 mg/day",
          "titration": "May increase to 150 mg BID within 1 week; max 225 mg BID",
          "notes": "FDA-approved for fibromyalgia"
        },
        "epilepsy": {
          "indication": "Adjunctive therapy for partial seizures",
          "doseOptions": [
            {"text": "50 mg TID", "orderSentence": "Pregabalin 50 mg PO TID"},
            {"text": "100 mg TID", "orderSentence": "Pregabalin 100 mg PO TID"},
            {"text": "150 mg BID", "orderSentence": "Pregabalin 150 mg PO BID"},
            {"text": "200 mg BID", "orderSentence": "Pregabalin 200 mg BID"},
            {"text": "300 mg BID", "orderSentence": "Pregabalin 300 mg PO BID"}
          ],
          "startingDose": "50 mg TID or 75 mg BID",
          "maxDose": "600 mg/day",
          "titration": "Increase based on response and tolerability",
          "notes": "Adjunctive therapy only"
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": ["Known hypersensitivity to pregabalin"],
        "precautions": [
          "Respiratory depression risk when combined with CNS depressants or opioids",
          "Suicidal ideation (class warning for antiepileptics)",
          "Angioedema (rare but serious)",
          "Peripheral edema and weight gain",
          "Schedule V controlled substance - abuse potential",
          "Dizziness and somnolence - fall risk"
        ],
        "drugInteractions": [
          {"drug": "Opioids", "severity": "high", "effect": "Increased respiratory depression risk"},
          {"drug": "CNS depressants", "severity": "moderate", "effect": "Additive sedation"},
          {"drug": "Thiazolidinediones (pioglitazone, rosiglitazone)", "severity": "moderate", "effect": "Increased peripheral edema and weight gain"}
        ],
        "pregnancyCategory": "C",
        "lactation": "Likely compatible but limited data"
      },
      "renalAdjustment": {
        "required": true,
        "tiers": [
          {"gfr": "≥60", "adjustment": "No adjustment needed"},
          {"gfr": "30-59", "adjustment": "Reduce dose by 50% (max 300 mg/day)"},
          {"gfr": "15-29", "adjustment": "Reduce dose by 75% (max 150 mg/day)"},
          {"gfr": "<15", "adjustment": "Max 75 mg/day"},
          {"gfr": "HD", "adjustment": "25-75 mg daily; supplemental dose after dialysis"}
        ]
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": "No adjustment needed - not hepatically metabolized"
      },
      "monitoring": {
        "baseline": ["Renal function (BMP/CrCl)"],
        "ongoing": ["Renal function periodically", "Weight", "Peripheral edema", "Suicidal ideation"],
        "frequency": "Renal function annually or with changes"
      },
      "patientCounseling": [
        "Do not stop abruptly - taper over 1 week minimum",
        "Controlled substance - take only as prescribed",
        "May cause drowsiness, weight gain, swelling",
        "Report mood changes, swelling of face/tongue, or difficulty breathing immediately"
      ]
    },
    "duloxetine": {
      "id": "duloxetine",
      "name": "Duloxetine",
      "genericName": "duloxetine",
      "brandNames": ["Cymbalta", "Drizalma"],
      "drugClass": "SNRI (Serotonin-Norepinephrine Reuptake Inhibitor)",
      "mechanisms": ["Inhibits reuptake of serotonin and norepinephrine", "Descending pain inhibition pathway modulation"],
      "routes": ["PO"],
      "formulations": ["20 mg capsule", "30 mg capsule", "40 mg capsule", "60 mg capsule"],
      "contexts": {
        "neuropathic-pain": {
          "indication": "Diabetic peripheral neuropathy, neuropathic pain",
          "doseOptions": [
            {"text": "30 mg daily", "orderSentence": "Duloxetine 30 mg PO daily"},
            {"text": "60 mg daily", "orderSentence": "Duloxetine 60 mg PO daily"},
            {"text": "90 mg daily", "orderSentence": "Duloxetine 90 mg PO daily"},
            {"text": "120 mg daily", "orderSentence": "Duloxetine 120 mg PO daily"}
          ],
          "startingDose": "30 mg daily (to minimize nausea)",
          "maxDose": "120 mg/day",
          "titration": "Start 30 mg daily x 1-2 weeks, then increase to 60 mg daily",
          "notes": "FDA-approved for DPNP; first-line option"
        },
        "fibromyalgia": {
          "indication": "Fibromyalgia",
          "doseOptions": [
            {"text": "30 mg daily", "orderSentence": "Duloxetine 30 mg PO daily"},
            {"text": "60 mg daily", "orderSentence": "Duloxetine 60 mg PO daily"}
          ],
          "startingDose": "30 mg daily",
          "maxDose": "60 mg/day",
          "titration": "Start 30 mg daily x 1 week, then increase to 60 mg daily",
          "notes": "FDA-approved; doses above 60 mg show no additional benefit for fibromyalgia"
        },
        "depression-anxiety": {
          "indication": "Major depressive disorder, generalized anxiety disorder",
          "doseOptions": [
            {"text": "30 mg daily", "orderSentence": "Duloxetine 30 mg PO daily"},
            {"text": "60 mg daily", "orderSentence": "Duloxetine 60 mg PO daily"},
            {"text": "90 mg daily", "orderSentence": "Duloxetine 90 mg PO daily"},
            {"text": "120 mg daily", "orderSentence": "Duloxetine 120 mg PO daily"}
          ],
          "startingDose": "30-60 mg daily",
          "maxDose": "120 mg/day",
          "titration": "May increase by 30 mg increments",
          "notes": "Dual benefit when comorbid depression/anxiety with chronic pain"
        }
      },
      "safety": {
        "blackBoxWarnings": [
          "Suicidal thinking and behavior in children, adolescents, and young adults with MDD and other psychiatric disorders"
        ],
        "contraindications": [
          "Use within 14 days of MAOIs",
          "Concomitant use with linezolid or IV methylene blue",
          "Uncontrolled narrow-angle glaucoma",
          "Severe hepatic impairment"
        ],
        "precautions": [
          "Serotonin syndrome risk with serotonergic drugs",
          "Hepatotoxicity - monitor LFTs",
          "Increased bleeding risk especially with anticoagulants/NSAIDs",
          "Hyponatremia (SIADH) especially in elderly",
          "Discontinuation syndrome - taper slowly",
          "May elevate blood pressure - monitor"
        ],
        "drugInteractions": [
          {"drug": "MAOIs", "severity": "contraindicated", "effect": "Risk of serotonin syndrome"},
          {"drug": "Triptans", "severity": "high", "effect": "Serotonin syndrome risk"},
          {"drug": "Tramadol", "severity": "high", "effect": "Serotonin syndrome risk, seizure threshold lowered"},
          {"drug": "Warfarin", "severity": "moderate", "effect": "Increased bleeding risk"},
          {"drug": "NSAIDs", "severity": "moderate", "effect": "Increased bleeding risk"},
          {"drug": "CYP1A2 inhibitors (fluvoxamine, ciprofloxacin)", "severity": "high", "effect": "Increased duloxetine levels"},
          {"drug": "CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine)", "severity": "moderate", "effect": "Increased duloxetine levels"}
        ],
        "pregnancyCategory": "C",
        "lactation": "Caution - present in breast milk"
      },
      "renalAdjustment": {
        "required": true,
        "tiers": [
          {"gfr": "≥30", "adjustment": "No adjustment needed"},
          {"gfr": "<30", "adjustment": "Not recommended (AUC increased 2-fold)"},
          {"gfr": "HD", "adjustment": "Not recommended"}
        ]
      },
      "hepaticAdjustment": {
        "required": true,
        "notes": "Avoid in severe hepatic impairment (Child-Pugh C). Use caution in moderate impairment. Monitor LFTs."
      },
      "monitoring": {
        "baseline": ["LFTs", "Renal function", "Blood pressure"],
        "ongoing": ["Blood pressure", "LFTs if symptoms", "Suicidal ideation", "Signs of bleeding"],
        "frequency": "Blood pressure at each visit initially; LFTs PRN"
      },
      "patientCounseling": [
        "Do not stop abruptly - taper over 2+ weeks to avoid discontinuation syndrome",
        "May take 2-4 weeks for full pain relief; 4-6 weeks for antidepressant effect",
        "Take with food to minimize nausea",
        "Avoid alcohol",
        "Report unusual bleeding, mood changes, or allergic reactions",
        "Swallow capsule whole - do not crush or chew"
      ]
    },
    "amitriptyline": {
      "id": "amitriptyline",
      "name": "Amitriptyline",
      "genericName": "amitriptyline",
      "brandNames": ["Elavil"],
      "drugClass": "Tricyclic Antidepressant (TCA)",
      "mechanisms": ["Inhibits reuptake of serotonin and norepinephrine", "Anticholinergic effects", "Sodium channel blockade"],
      "routes": ["PO"],
      "formulations": ["10 mg tablet", "25 mg tablet", "50 mg tablet", "75 mg tablet", "100 mg tablet", "150 mg tablet"],
      "contexts": {
        "neuropathic-pain": {
          "indication": "Neuropathic pain (diabetic neuropathy, post-herpetic neuralgia)",
          "doseOptions": [
            {"text": "10 mg QHS", "orderSentence": "Amitriptyline 10 mg PO QHS"},
            {"text": "25 mg QHS", "orderSentence": "Amitriptyline 25 mg PO QHS"},
            {"text": "50 mg QHS", "orderSentence": "Amitriptyline 50 mg PO QHS"},
            {"text": "75 mg QHS", "orderSentence": "Amitriptyline 75 mg PO QHS"},
            {"text": "100 mg QHS", "orderSentence": "Amitriptyline 100 mg PO QHS"}
          ],
          "startingDose": "10-25 mg QHS",
          "maxDose": "150 mg/day (pain); lower in elderly",
          "titration": "Increase by 10-25 mg every 1-2 weeks as tolerated",
          "notes": "First-line TCA for neuropathic pain; sedation limits titration"
        },
        "migraine-prophylaxis": {
          "indication": "Migraine prophylaxis",
          "doseOptions": [
            {"text": "10 mg QHS", "orderSentence": "Amitriptyline 10 mg PO QHS"},
            {"text": "25 mg QHS", "orderSentence": "Amitriptyline 25 mg PO QHS"},
            {"text": "50 mg QHS", "orderSentence": "Amitriptyline 50 mg PO QHS"},
            {"text": "75 mg QHS", "orderSentence": "Amitriptyline 75 mg PO QHS"}
          ],
          "startingDose": "10 mg QHS",
          "maxDose": "100 mg/day",
          "titration": "Increase by 10 mg every 2 weeks",
          "notes": "First-line for migraine prophylaxis; helps with comorbid insomnia"
        },
        "tension-headache": {
          "indication": "Chronic tension-type headache prophylaxis",
          "doseOptions": [
            {"text": "10 mg QHS", "orderSentence": "Amitriptyline 10 mg PO QHS"},
            {"text": "25 mg QHS", "orderSentence": "Amitriptyline 25 mg PO QHS"},
            {"text": "50 mg QHS", "orderSentence": "Amitriptyline 50 mg PO QHS"},
            {"text": "75 mg QHS", "orderSentence": "Amitriptyline 75 mg PO QHS"}
          ],
          "startingDose": "10 mg QHS",
          "maxDose": "100 mg/day",
          "titration": "Increase by 10-25 mg every 1-2 weeks",
          "notes": "First-line for chronic tension headache"
        }
      },
      "safety": {
        "blackBoxWarnings": [
          "Suicidal thinking and behavior in children, adolescents, and young adults with MDD"
        ],
        "contraindications": [
          "Use within 14 days of MAOIs",
          "Acute recovery phase after myocardial infarction",
          "Concomitant use with cisapride"
        ],
        "precautions": [
          "Cardiac arrhythmias - ECG before starting in patients with cardiac history",
          "Anticholinergic effects (dry mouth, constipation, urinary retention, blurred vision)",
          "Orthostatic hypotension - fall risk in elderly",
          "Sedation - take at bedtime",
          "Lowered seizure threshold",
          "Angle-closure glaucoma risk",
          "QT prolongation at high doses",
          "AVOID in elderly (Beers Criteria - highly anticholinergic)"
        ],
        "drugInteractions": [
          {"drug": "MAOIs", "severity": "contraindicated", "effect": "Hypertensive crisis, serotonin syndrome"},
          {"drug": "Anticholinergics", "severity": "high", "effect": "Additive anticholinergic toxicity"},
          {"drug": "QT-prolonging drugs", "severity": "high", "effect": "Additive QT prolongation"},
          {"drug": "Alcohol", "severity": "moderate", "effect": "Additive CNS depression"},
          {"drug": "CYP2D6 inhibitors", "severity": "moderate", "effect": "Increased amitriptyline levels"}
        ],
        "pregnancyCategory": "C",
        "lactation": "Caution - excreted in breast milk"
      },
      "renalAdjustment": {
        "required": false,
        "tiers": [
          {"gfr": "≥15", "adjustment": "No adjustment typically needed"},
          {"gfr": "<15", "adjustment": "Use with caution; active metabolites may accumulate"}
        ]
      },
      "hepaticAdjustment": {
        "required": true,
        "notes": "Use lower doses; hepatically metabolized. Avoid in severe impairment."
      },
      "monitoring": {
        "baseline": ["ECG if cardiac history or age >50", "Consider baseline cognitive assessment in elderly"],
        "ongoing": ["Anticholinergic side effects", "Orthostatic hypotension", "Suicidal ideation"],
        "frequency": "Clinical assessment at each visit"
      },
      "patientCounseling": [
        "Take at bedtime due to sedation",
        "Do not stop abruptly - taper over 2+ weeks",
        "Avoid alcohol",
        "May cause dry mouth - sip water, sugar-free gum",
        "Rise slowly to prevent dizziness",
        "Full effect may take 4-6 weeks",
        "Avoid in very hot weather (impaired sweating)"
      ]
    },
    "carbamazepine": {
      "id": "carbamazepine",
      "name": "Carbamazepine",
      "genericName": "carbamazepine",
      "brandNames": ["Tegretol", "Tegretol XR", "Carbatrol", "Epitol"],
      "drugClass": "Anticonvulsant / Sodium Channel Blocker",
      "mechanisms": ["Blocks voltage-gated sodium channels", "Reduces repetitive neuronal firing"],
      "routes": ["PO"],
      "formulations": ["100 mg chewable tablet", "200 mg tablet", "100 mg/5mL suspension", "100 mg XR capsule", "200 mg XR tablet", "300 mg XR capsule", "400 mg XR tablet"],
      "contexts": {
        "trigeminal-neuralgia": {
          "indication": "Trigeminal neuralgia (first-line)",
          "doseOptions": [
            {"text": "100 mg BID", "orderSentence": "Carbamazepine 100 mg PO BID"},
            {"text": "200 mg BID", "orderSentence": "Carbamazepine 200 mg PO BID"},
            {"text": "400 mg BID", "orderSentence": "Carbamazepine 400 mg PO BID"},
            {"text": "600 mg BID", "orderSentence": "Carbamazepine 600 mg PO BID"}
          ],
          "startingDose": "100 mg BID",
          "maxDose": "1200 mg/day",
          "titration": "Increase by 100-200 mg every 1-2 weeks",
          "notes": "First-line for trigeminal neuralgia; NNT ~1.7"
        },
        "epilepsy": {
          "indication": "Partial seizures, generalized tonic-clonic seizures",
          "doseOptions": [
            {"text": "200 mg BID", "orderSentence": "Carbamazepine 200 mg PO BID"},
            {"text": "400 mg BID", "orderSentence": "Carbamazepine 400 mg PO BID"},
            {"text": "600 mg BID", "orderSentence": "Carbamazepine 600 mg PO BID"},
            {"text": "800 mg BID", "orderSentence": "Carbamazepine 800 mg PO BID"}
          ],
          "startingDose": "200 mg BID",
          "maxDose": "1600 mg/day (adults); adjust by level",
          "titration": "Increase by 200 mg weekly",
          "notes": "First-line for focal epilepsy; induces own metabolism (autoinduction)"
        },
        "neuropathic-pain": {
          "indication": "Neuropathic pain (second-line)",
          "doseOptions": [
            {"text": "100 mg BID", "orderSentence": "Carbamazepine 100 mg PO BID"},
            {"text": "200 mg BID", "orderSentence": "Carbamazepine 200 mg PO BID"},
            {"text": "400 mg BID", "orderSentence": "Carbamazepine 400 mg PO BID"}
          ],
          "startingDose": "100 mg BID",
          "maxDose": "1200 mg/day",
          "titration": "Increase by 100-200 mg every 1-2 weeks",
          "notes": "Consider for lancinating/shooting pain; many drug interactions"
        }
      },
      "safety": {
        "blackBoxWarnings": [
          "Serious dermatologic reactions (SJS/TEN) - HLA-B*1502 screening required in Asian populations",
          "Aplastic anemia and agranulocytosis (rare but serious)"
        ],
        "contraindications": [
          "Known HLA-B*1502 allele",
          "Bone marrow depression",
          "Use within 14 days of MAOIs",
          "Concomitant use with nefazodone"
        ],
        "precautions": [
          "Hyponatremia (SIADH)",
          "Cardiac conduction abnormalities",
          "Hepatotoxicity",
          "Potent CYP3A4 inducer - many drug interactions",
          "Autoinduction - levels decrease over first 2-4 weeks",
          "May worsen absence, myoclonic seizures"
        ],
        "drugInteractions": [
          {"drug": "Oral contraceptives", "severity": "high", "effect": "Reduced contraceptive efficacy - use backup method"},
          {"drug": "Warfarin", "severity": "high", "effect": "Reduced warfarin effect - monitor INR"},
          {"drug": "Valproate", "severity": "moderate", "effect": "Reduced valproate levels; increased carbamazepine epoxide"},
          {"drug": "Lamotrigine", "severity": "moderate", "effect": "Reduced lamotrigine levels by 40%"},
          {"drug": "CYP3A4 substrates (many)", "severity": "high", "effect": "Reduced levels of substrate drugs"}
        ],
        "pregnancyCategory": "D",
        "lactation": "Compatible but monitor infant for sedation"
      },
      "renalAdjustment": {
        "required": false,
        "tiers": [
          {"gfr": "≥10", "adjustment": "No adjustment typically needed"},
          {"gfr": "<10", "adjustment": "75% of normal dose; use with caution"}
        ]
      },
      "hepaticAdjustment": {
        "required": true,
        "notes": "Reduce dose in hepatic impairment; hepatically metabolized. Avoid in severe impairment."
      },
      "monitoring": {
        "baseline": ["CBC with differential", "LFTs", "BMP (sodium)", "HLA-B*1502 in at-risk populations"],
        "ongoing": ["Sodium levels", "CBC", "LFTs", "Carbamazepine level (therapeutic: 4-12 mcg/mL)"],
        "frequency": "CBC and sodium monthly x 3 months, then every 3-6 months"
      },
      "patientCounseling": [
        "Take with food to reduce GI upset",
        "Report any rash, fever, sore throat, mouth ulcers immediately (stop drug if rash)",
        "Do not stop abruptly - seizure risk",
        "Many drug interactions - inform all providers",
        "May reduce effectiveness of birth control pills",
        "Avoid grapefruit juice"
      ]
    },
    "propranolol": {
      "id": "propranolol",
      "name": "Propranolol",
      "genericName": "propranolol",
      "brandNames": ["Inderal", "Inderal LA", "InnoPran XL"],
      "drugClass": "Non-selective Beta-Blocker",
      "mechanisms": ["Blocks beta-1 and beta-2 adrenergic receptors", "Reduces sympathetic nervous system activity"],
      "routes": ["PO", "IV"],
      "formulations": ["10 mg tablet", "20 mg tablet", "40 mg tablet", "60 mg tablet", "80 mg tablet", "60 mg LA capsule", "80 mg LA capsule", "120 mg LA capsule", "160 mg LA capsule", "1 mg/mL IV solution"],
      "contexts": {
        "essential-tremor": {
          "indication": "Essential tremor (first-line)",
          "doseOptions": [
            {"text": "20 mg BID", "orderSentence": "Propranolol 20 mg PO BID"},
            {"text": "40 mg BID", "orderSentence": "Propranolol 40 mg PO BID"},
            {"text": "60 mg TID", "orderSentence": "Propranolol 60 mg PO TID"},
            {"text": "80 mg TID", "orderSentence": "Propranolol 80 mg PO TID"}
          ],
          "startingDose": "20-40 mg BID",
          "maxDose": "320 mg/day",
          "titration": "Increase every 1-2 weeks as tolerated",
          "notes": "First-line for essential tremor; 50-70% response rate"
        },
        "migraine-prophylaxis": {
          "indication": "Migraine prophylaxis",
          "doseOptions": [
            {"text": "40 mg BID", "orderSentence": "Propranolol 40 mg PO BID"},
            {"text": "60 mg BID", "orderSentence": "Propranolol 60 mg PO BID"},
            {"text": "80 mg BID", "orderSentence": "Propranolol 80 mg PO BID"},
            {"text": "80 mg LA daily", "orderSentence": "Propranolol LA 80 mg PO daily"},
            {"text": "160 mg LA daily", "orderSentence": "Propranolol LA 160 mg PO daily"}
          ],
          "startingDose": "40 mg BID or 80 mg LA daily",
          "maxDose": "240 mg/day",
          "titration": "Increase every 2-4 weeks",
          "notes": "First-line for migraine prophylaxis; Level A evidence"
        },
        "akathisia": {
          "indication": "Drug-induced akathisia",
          "doseOptions": [
            {"text": "10 mg TID", "orderSentence": "Propranolol 10 mg PO TID"},
            {"text": "20 mg TID", "orderSentence": "Propranolol 20 mg PO TID"},
            {"text": "40 mg TID", "orderSentence": "Propranolol 40 mg PO TID"}
          ],
          "startingDose": "10-20 mg TID",
          "maxDose": "120 mg/day",
          "titration": "Increase as needed for symptom control",
          "notes": "First-line for neuroleptic-induced akathisia"
        }
      },
      "safety": {
        "blackBoxWarnings": [
          "Do not discontinue abruptly - risk of exacerbation of angina, MI, or arrhythmia"
        ],
        "contraindications": [
          "Cardiogenic shock",
          "Sinus bradycardia, heart block greater than first degree",
          "Bronchial asthma or severe COPD",
          "Decompensated heart failure"
        ],
        "precautions": [
          "May mask hypoglycemia symptoms in diabetics",
          "May worsen peripheral vascular disease",
          "Use with caution in hepatic impairment",
          "May worsen psoriasis",
          "Fatigue, exercise intolerance common",
          "May cause depression"
        ],
        "drugInteractions": [
          {"drug": "Calcium channel blockers (verapamil, diltiazem)", "severity": "high", "effect": "Risk of severe bradycardia and heart block"},
          {"drug": "Clonidine", "severity": "high", "effect": "Rebound hypertension if clonidine stopped first"},
          {"drug": "Antidiabetics", "severity": "moderate", "effect": "Masks hypoglycemia symptoms; prolongs hypoglycemia"},
          {"drug": "CYP2D6 inhibitors", "severity": "moderate", "effect": "Increased propranolol levels"},
          {"drug": "Epinephrine", "severity": "moderate", "effect": "Hypertensive response, bradycardia"}
        ],
        "pregnancyCategory": "C",
        "lactation": "Compatible with breastfeeding"
      },
      "renalAdjustment": {
        "required": false,
        "tiers": [
          {"gfr": "any", "adjustment": "No adjustment needed - hepatically metabolized"}
        ]
      },
      "hepaticAdjustment": {
        "required": true,
        "notes": "Reduce dose by 50% in hepatic impairment; extensive first-pass metabolism"
      },
      "monitoring": {
        "baseline": ["Heart rate", "Blood pressure", "ECG if cardiac history"],
        "ongoing": ["Heart rate", "Blood pressure", "Signs of heart failure"],
        "frequency": "At each visit during titration"
      },
      "patientCounseling": [
        "Do not stop abruptly - taper over 1-2 weeks",
        "May cause fatigue, especially initially",
        "Take pulse - notify if <50 bpm",
        "Diabetics: may mask hypoglycemia symptoms",
        "May worsen asthma - use with extreme caution"
      ]
    },
    "levetiracetam": {
      "id": "levetiracetam",
      "name": "Levetiracetam",
      "genericName": "levetiracetam",
      "brandNames": ["Keppra", "Keppra XR", "Spritam", "Elepsia XR"],
      "drugClass": "Anticonvulsant",
      "mechanisms": ["Binds synaptic vesicle protein SV2A", "Modulates neurotransmitter release"],
      "routes": ["PO", "IV"],
      "formulations": ["250 mg tablet", "500 mg tablet", "750 mg tablet", "1000 mg tablet", "500 mg XR tablet", "750 mg XR tablet", "100 mg/mL oral solution", "100 mg/mL IV solution"],
      "contexts": {
        "epilepsy-partial": {
          "indication": "Partial onset seizures (focal epilepsy)",
          "doseOptions": [
            {"text": "250 mg BID", "orderSentence": "Levetiracetam 250 mg PO BID"},
            {"text": "500 mg BID", "orderSentence": "Levetiracetam 500 mg PO BID"},
            {"text": "750 mg BID", "orderSentence": "Levetiracetam 750 mg PO BID"},
            {"text": "1000 mg BID", "orderSentence": "Levetiracetam 1000 mg PO BID"},
            {"text": "1500 mg BID", "orderSentence": "Levetiracetam 1500 mg PO BID"}
          ],
          "startingDose": "500 mg BID",
          "maxDose": "3000 mg/day",
          "titration": "May increase by 500 mg BID every 2 weeks",
          "notes": "First-line for focal epilepsy; no titration required but may help tolerability"
        },
        "epilepsy-generalized": {
          "indication": "Generalized tonic-clonic seizures, myoclonic seizures",
          "doseOptions": [
            {"text": "500 mg BID", "orderSentence": "Levetiracetam 500 mg PO BID"},
            {"text": "750 mg BID", "orderSentence": "Levetiracetam 750 mg PO BID"},
            {"text": "1000 mg BID", "orderSentence": "Levetiracetam 1000 mg PO BID"},
            {"text": "1500 mg BID", "orderSentence": "Levetiracetam 1500 mg PO BID"}
          ],
          "startingDose": "500 mg BID",
          "maxDose": "3000 mg/day",
          "titration": "Increase by 500 mg BID every 2 weeks",
          "notes": "Effective for JME; good for mixed seizure types"
        },
        "seizure-prophylaxis-acute": {
          "indication": "Seizure prophylaxis (post-TBI, post-craniotomy, ICH)",
          "doseOptions": [
            {"text": "500 mg IV q12h", "orderSentence": "Levetiracetam 500 mg IV q12h"},
            {"text": "1000 mg IV q12h", "orderSentence": "Levetiracetam 1000 mg IV q12h"},
            {"text": "1500 mg IV load then 1000 mg IV q12h", "orderSentence": "Levetiracetam 1500 mg IV load then 1000 mg IV q12h"}
          ],
          "startingDose": "1000 mg IV q12h (or 20 mg/kg load)",
          "maxDose": "3000 mg/day",
          "titration": "N/A for acute prophylaxis",
          "notes": "Duration typically 7 days post-TBI; IV=PO bioequivalent"
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": ["Known hypersensitivity to levetiracetam"],
        "precautions": [
          "Behavioral/psychiatric adverse events (irritability, aggression, anxiety, depression)",
          "Suicidal ideation (class warning)",
          "Somnolence and fatigue",
          "Coordination difficulties",
          "Anaphylaxis and angioedema (rare)"
        ],
        "drugInteractions": [
          {"drug": "CNS depressants", "severity": "low", "effect": "Additive sedation"},
          {"drug": "No significant CYP interactions", "severity": "none", "effect": "Few drug interactions - major advantage"}
        ],
        "pregnancyCategory": "C",
        "lactation": "Likely compatible"
      },
      "renalAdjustment": {
        "required": true,
        "tiers": [
          {"gfr": "≥80", "adjustment": "No adjustment needed"},
          {"gfr": "50-79", "adjustment": "500-1000 mg BID (max 2000 mg/day)"},
          {"gfr": "30-49", "adjustment": "250-750 mg BID (max 1500 mg/day)"},
          {"gfr": "<30", "adjustment": "250-500 mg BID (max 1000 mg/day)"},
          {"gfr": "HD", "adjustment": "500-1000 mg daily + 250-500 mg supplement post-dialysis"}
        ]
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": "No adjustment needed - renally eliminated"
      },
      "monitoring": {
        "baseline": ["Renal function"],
        "ongoing": ["Behavioral changes", "Mood", "Suicidal ideation"],
        "frequency": "Renal function annually; behavioral assessment at each visit"
      },
      "patientCounseling": [
        "Report mood changes, irritability, aggression, depression, or suicidal thoughts immediately",
        "May cause drowsiness - avoid driving until effects known",
        "Do not stop abruptly - may precipitate seizures",
        "Keppra Rage is real - discuss with provider if mood changes",
        "Pyridoxine (B6) may help with irritability"
      ]
    },
    "sumatriptan": {
      "id": "sumatriptan",
      "name": "Sumatriptan",
      "genericName": "sumatriptan",
      "brandNames": ["Imitrex", "Onzetra Xsail", "Tosymra", "Zembrace"],
      "drugClass": "Triptan / 5-HT1B/1D Agonist",
      "mechanisms": ["Selective serotonin 5-HT1B/1D receptor agonist", "Causes cranial vasoconstriction", "Inhibits trigeminal nerve activation"],
      "routes": ["PO", "SC", "Nasal"],
      "formulations": ["25 mg tablet", "50 mg tablet", "100 mg tablet", "6 mg/0.5mL SC injection", "4 mg/0.5mL SC injection", "5 mg nasal spray", "10 mg nasal spray", "20 mg nasal spray"],
      "contexts": {
        "migraine-acute": {
          "indication": "Acute migraine treatment",
          "doseOptions": [
            {"text": "25 mg PO PRN", "orderSentence": "Sumatriptan 25 mg PO PRN migraine"},
            {"text": "50 mg PO PRN", "orderSentence": "Sumatriptan 50 mg PO PRN migraine"},
            {"text": "100 mg PO PRN", "orderSentence": "Sumatriptan 100 mg PO PRN migraine"},
            {"text": "6 mg SC PRN", "orderSentence": "Sumatriptan 6 mg SC PRN migraine"},
            {"text": "20 mg nasal PRN", "orderSentence": "Sumatriptan 20 mg nasal spray PRN migraine"}
          ],
          "startingDose": "50 mg PO (or 6 mg SC for faster relief)",
          "maxDose": "200 mg PO/day; 12 mg SC/day; 40 mg nasal/day",
          "titration": "N/A - use lowest effective dose",
          "notes": "Take at onset of headache; may repeat in 2 hours if needed; SC fastest onset"
        },
        "cluster-headache-acute": {
          "indication": "Acute cluster headache treatment",
          "doseOptions": [
            {"text": "6 mg SC PRN", "orderSentence": "Sumatriptan 6 mg SC PRN cluster headache"},
            {"text": "20 mg nasal PRN", "orderSentence": "Sumatriptan 20 mg nasal spray PRN cluster headache"}
          ],
          "startingDose": "6 mg SC",
          "maxDose": "12 mg SC/day (two injections)",
          "titration": "N/A",
          "notes": "SC or nasal preferred over oral for cluster headache due to faster onset"
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "History of coronary artery disease, MI, Prinzmetal angina",
          "History of stroke or TIA",
          "Peripheral vascular disease",
          "Uncontrolled hypertension",
          "Hemiplegic or basilar migraine",
          "Use within 24 hours of another triptan or ergot",
          "Use within 2 weeks of MAOIs",
          "Severe hepatic impairment"
        ],
        "precautions": [
          "Chest tightness/pressure (triptan sensations - usually benign)",
          "Cardiovascular evaluation before use in patients with risk factors",
          "Serotonin syndrome with SSRIs/SNRIs (rare but possible)",
          "Medication overuse headache with frequent use (>10 days/month)"
        ],
        "drugInteractions": [
          {"drug": "Ergots", "severity": "contraindicated", "effect": "Additive vasospasm - separate by 24 hours"},
          {"drug": "Other triptans", "severity": "contraindicated", "effect": "Additive vasospasm - separate by 24 hours"},
          {"drug": "MAOIs", "severity": "contraindicated", "effect": "Increased sumatriptan levels - avoid within 2 weeks"},
          {"drug": "SSRIs/SNRIs", "severity": "moderate", "effect": "Risk of serotonin syndrome (rare)"}
        ],
        "pregnancyCategory": "C",
        "lactation": "Compatible - express and discard milk for 12 hours if concerned"
      },
      "renalAdjustment": {
        "required": false,
        "tiers": [
          {"gfr": "any", "adjustment": "No adjustment needed"}
        ]
      },
      "hepaticAdjustment": {
        "required": true,
        "notes": "Max 50 mg PO in mild-moderate impairment; contraindicated in severe impairment"
      },
      "monitoring": {
        "baseline": ["Cardiovascular risk assessment", "Blood pressure"],
        "ongoing": ["Headache frequency (watch for MOH)", "Cardiovascular symptoms"],
        "frequency": "At each visit; limit to <10 days/month to prevent MOH"
      },
      "patientCounseling": [
        "Take at first sign of migraine headache (not during aura)",
        "May repeat in 2 hours if needed; max 2 doses/day",
        "Do not use more than 10 days per month (medication overuse headache risk)",
        "Chest tightness is common and usually benign - but report if severe or persistent",
        "Do not use if you have heart disease or uncontrolled blood pressure",
        "Store injectable away from light"
      ]
    },
    "prednisone": {
      "id": "prednisone",
      "name": "Prednisone",
      "genericName": "prednisone",
      "brandNames": ["Deltasone", "Rayos"],
      "drugClass": "Corticosteroid / Glucocorticoid",
      "mechanisms": ["Binds glucocorticoid receptor", "Suppresses inflammatory and immune responses", "Reduces cytokine production"],
      "routes": ["PO"],
      "formulations": ["1 mg tablet", "2.5 mg tablet", "5 mg tablet", "10 mg tablet", "20 mg tablet", "50 mg tablet", "5 mg/mL solution"],
      "contexts": {
        "ms-acute-relapse": {
          "indication": "Multiple sclerosis acute relapse",
          "doseOptions": [
            {"text": "1000 mg IV daily x3-5 days", "orderSentence": "Methylprednisolone 1000 mg IV daily x3-5 days"},
            {"text": "1250 mg PO daily x3-5 days", "orderSentence": "Prednisone 1250 mg PO daily x3-5 days"}
          ],
          "startingDose": "1000 mg IV methylprednisolone (or 1250 mg PO prednisone equivalent)",
          "maxDose": "1000-1250 mg/day x 3-5 days",
          "titration": "No taper needed for short courses",
          "notes": "High-dose steroids speed recovery from relapse but don't affect long-term disability"
        },
        "myasthenia-gravis": {
          "indication": "Myasthenia gravis",
          "doseOptions": [
            {"text": "20 mg daily", "orderSentence": "Prednisone 20 mg PO daily"},
            {"text": "40 mg daily", "orderSentence": "Prednisone 40 mg PO daily"},
            {"text": "60 mg daily", "orderSentence": "Prednisone 60 mg PO daily"},
            {"text": "1 mg/kg daily", "orderSentence": "Prednisone 1 mg/kg PO daily"}
          ],
          "startingDose": "10-20 mg daily (or low-dose escalation to avoid exacerbation)",
          "maxDose": "1-1.5 mg/kg/day (usually 60-100 mg)",
          "titration": "Increase by 10 mg every 3-5 days OR start high and taper; risk of transient worsening",
          "notes": "May cause transient worsening in first 2-3 weeks; inpatient initiation may be safer"
        },
        "inflammatory-neuropathy": {
          "indication": "CIDP, vasculitic neuropathy, inflammatory neuropathies",
          "doseOptions": [
            {"text": "60 mg daily", "orderSentence": "Prednisone 60 mg PO daily"},
            {"text": "1 mg/kg daily", "orderSentence": "Prednisone 1 mg/kg PO daily"}
          ],
          "startingDose": "60 mg daily or 1 mg/kg/day",
          "maxDose": "100 mg/day",
          "titration": "Treat for 2-4 weeks then taper over months",
          "notes": "For CIDP, IVIG often preferred first-line; steroids for refractory cases or vasculitis"
        },
        "bells-palsy": {
          "indication": "Bell's palsy",
          "doseOptions": [
            {"text": "60 mg daily x7 days then taper", "orderSentence": "Prednisone 60 mg PO daily x7 days then taper"},
            {"text": "50 mg daily x10 days", "orderSentence": "Prednisone 50 mg PO daily x10 days"}
          ],
          "startingDose": "60 mg daily",
          "maxDose": "60 mg/day",
          "titration": "7-10 day course; can taper over 5 days or stop",
          "notes": "Start within 72 hours of onset for best effect"
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Systemic fungal infections",
          "Known hypersensitivity"
        ],
        "precautions": [
          "Hyperglycemia - monitor blood glucose in diabetics",
          "Immunosuppression - increased infection risk",
          "Adrenal suppression with prolonged use - taper required",
          "Osteoporosis with chronic use",
          "GI bleeding risk - consider PPI if risk factors",
          "Psychiatric effects (insomnia, mood changes, psychosis)",
          "Hypertension, fluid retention",
          "Cataracts and glaucoma with prolonged use",
          "AVN of femoral head (rare)"
        ],
        "drugInteractions": [
          {"drug": "NSAIDs", "severity": "moderate", "effect": "Increased GI bleeding risk"},
          {"drug": "CYP3A4 inducers (phenytoin, rifampin)", "severity": "moderate", "effect": "Decreased prednisone effect"},
          {"drug": "Warfarin", "severity": "moderate", "effect": "Variable effect on INR - monitor closely"},
          {"drug": "Fluoroquinolones", "severity": "moderate", "effect": "Increased tendon rupture risk"},
          {"drug": "Live vaccines", "severity": "high", "effect": "Avoid live vaccines during immunosuppression"}
        ],
        "pregnancyCategory": "C (D in first trimester at high doses)",
        "lactation": "Compatible at low doses"
      },
      "renalAdjustment": {
        "required": false,
        "tiers": [
          {"gfr": "any", "adjustment": "No adjustment needed"}
        ]
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": "No adjustment typically needed; prednisone is prodrug converted to prednisolone"
      },
      "monitoring": {
        "baseline": ["Blood glucose", "Blood pressure", "BMD if chronic use anticipated"],
        "ongoing": ["Blood glucose", "Blood pressure", "Weight", "Signs of infection", "Mood changes"],
        "frequency": "Glucose frequently during high-dose; BP at each visit"
      },
      "patientCounseling": [
        "Take with food to reduce stomach upset",
        "Do not stop abruptly if on >7-10 days - must taper",
        "May cause insomnia - take in morning",
        "Monitor blood sugar if diabetic",
        "Report signs of infection, GI bleeding, or mood changes",
        "Consider calcium/vitamin D supplementation if prolonged use"
      ]
    },
    "pyridostigmine": {
      "id": "pyridostigmine",
      "name": "Pyridostigmine",
      "genericName": "pyridostigmine bromide",
      "brandNames": ["Mestinon", "Mestinon Timespan", "Regonol"],
      "drugClass": "Acetylcholinesterase Inhibitor",
      "mechanisms": ["Inhibits acetylcholinesterase", "Increases acetylcholine at neuromuscular junction"],
      "routes": ["PO", "IV", "IM"],
      "formulations": ["60 mg tablet", "180 mg extended-release tablet", "60 mg/5mL syrup", "5 mg/mL injection"],
      "contexts": {
        "myasthenia-gravis": {
          "indication": "Myasthenia gravis - symptomatic treatment",
          "doseOptions": [
            {"text": "30 mg TID", "orderSentence": "Pyridostigmine 30 mg PO TID"},
            {"text": "60 mg TID", "orderSentence": "Pyridostigmine 60 mg PO TID"},
            {"text": "60 mg QID", "orderSentence": "Pyridostigmine 60 mg PO QID"},
            {"text": "90 mg TID", "orderSentence": "Pyridostigmine 90 mg PO TID"},
            {"text": "120 mg TID", "orderSentence": "Pyridostigmine 120 mg PO TID"}
          ],
          "startingDose": "30-60 mg TID",
          "maxDose": "120 mg q3h (rarely >600-720 mg/day needed)",
          "titration": "Increase by 30-60 mg per dose every 3-7 days as needed",
          "notes": "Symptomatic only - does not modify disease; use lowest effective dose"
        },
        "myasthenia-gravis-severe": {
          "indication": "Myasthenia gravis - severe/crisis (NPO patients)",
          "doseOptions": [
            {"text": "2 mg IV q2-3h", "orderSentence": "Pyridostigmine 2 mg IV q2-3h"}
          ],
          "startingDose": "1-2 mg IV q2-3h",
          "maxDose": "Titrate to effect",
          "titration": "N/A - use for NPO patients only",
          "notes": "IV dose is 1/30 of oral dose; use only when oral not possible"
        },
        "orthostatic-hypotension": {
          "indication": "Neurogenic orthostatic hypotension",
          "doseOptions": [
            {"text": "30 mg TID", "orderSentence": "Pyridostigmine 30 mg PO TID"},
            {"text": "60 mg TID", "orderSentence": "Pyridostigmine 60 mg PO TID"}
          ],
          "startingDose": "30 mg TID",
          "maxDose": "60 mg TID",
          "titration": "Increase as tolerated",
          "notes": "Off-label; augments ganglionic transmission without supine hypertension"
        }
      },
      "safety": {
        "blackBoxWarnings": [],
        "contraindications": [
          "Mechanical GI or urinary obstruction",
          "Known hypersensitivity"
        ],
        "precautions": [
          "Cholinergic crisis with overdose (excessive secretions, bradycardia, weakness)",
          "Distinguish myasthenic crisis from cholinergic crisis",
          "Bronchospasm in asthmatics",
          "GI effects (cramping, diarrhea, nausea)",
          "Bradycardia",
          "Increased secretions"
        ],
        "drugInteractions": [
          {"drug": "Anticholinergics", "severity": "high", "effect": "Antagonize pyridostigmine effect"},
          {"drug": "Aminoglycosides", "severity": "moderate", "effect": "May worsen myasthenia"},
          {"drug": "Beta-blockers", "severity": "moderate", "effect": "Additive bradycardia"},
          {"drug": "Succinylcholine", "severity": "moderate", "effect": "Prolonged neuromuscular blockade"}
        ],
        "pregnancyCategory": "C",
        "lactation": "Compatible - poorly excreted in milk"
      },
      "renalAdjustment": {
        "required": true,
        "tiers": [
          {"gfr": "≥30", "adjustment": "No adjustment typically needed"},
          {"gfr": "<30", "adjustment": "Reduce dose; renally excreted"}
        ]
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": "No adjustment needed"
      },
      "monitoring": {
        "baseline": ["Clinical assessment of MG symptoms"],
        "ongoing": ["Symptom control", "Signs of cholinergic excess (SLUDGE)", "Heart rate"],
        "frequency": "Frequent initially to optimize dosing"
      },
      "patientCounseling": [
        "Take 30-60 minutes before meals",
        "Dose before activities requiring strength",
        "Report excessive salivation, sweating, diarrhea, or worsening weakness",
        "Carry medical ID indicating myasthenia gravis",
        "Do not take more than prescribed - overdose can worsen weakness"
      ]
    },
    "baclofen": {
      "id": "baclofen",
      "name": "Baclofen",
      "genericName": "baclofen",
      "brandNames": ["Lioresal", "Gablofen", "Ozobax"],
      "drugClass": "GABA-B Agonist / Skeletal Muscle Relaxant",
      "mechanisms": ["GABA-B receptor agonist", "Inhibits spinal cord reflex arcs", "Reduces muscle tone and spasms"],
      "routes": ["PO", "IT"],
      "formulations": ["5 mg tablet", "10 mg tablet", "20 mg tablet", "5 mg/5mL oral solution", "0.05 mg/mL IT", "0.5 mg/mL IT", "2 mg/mL IT"],
      "contexts": {
        "spasticity": {
          "indication": "Spasticity (MS, spinal cord injury, cerebral palsy, stroke)",
          "doseOptions": [
            {"text": "5 mg TID", "orderSentence": "Baclofen 5 mg PO TID"},
            {"text": "10 mg TID", "orderSentence": "Baclofen 10 mg PO TID"},
            {"text": "20 mg TID", "orderSentence": "Baclofen 20 mg PO TID"},
            {"text": "20 mg QID", "orderSentence": "Baclofen 20 mg PO QID"}
          ],
          "startingDose": "5 mg TID",
          "maxDose": "80 mg/day (20 mg QID); rarely up to 120 mg in select patients",
          "titration": "Increase by 5 mg TID every 3 days",
          "notes": "First-line for spasticity; gradual titration reduces sedation"
        },
        "trigeminal-neuralgia": {
          "indication": "Trigeminal neuralgia (adjunctive)",
          "doseOptions": [
            {"text": "10 mg TID", "orderSentence": "Baclofen 10 mg PO TID"},
            {"text": "20 mg TID", "orderSentence": "Baclofen 20 mg PO TID"}
          ],
          "startingDose": "5-10 mg TID",
          "maxDose": "60-80 mg/day",
          "titration": "Increase by 5-10 mg every 3 days",
          "notes": "Second-line; may be used with carbamazepine"
        },
        "hiccups": {
          "indication": "Intractable hiccups",
          "doseOptions": [
            {"text": "5 mg TID", "orderSentence": "Baclofen 5 mg PO TID"},
            {"text": "10 mg TID", "orderSentence": "Baclofen 10 mg PO TID"}
          ],
          "startingDose": "5 mg TID",
          "maxDose": "30 mg/day",
          "titration": "Increase as needed",
          "notes": "Off-label; evidence limited but commonly used"
        }
      },
      "safety": {
        "blackBoxWarnings": [
          "Abrupt discontinuation can cause serious withdrawal (hallucinations, seizures, hyperthermia, death)"
        ],
        "contraindications": [
          "Known hypersensitivity"
        ],
        "precautions": [
          "NEVER stop abruptly - life-threatening withdrawal",
          "Sedation and drowsiness",
          "Lowered seizure threshold",
          "Use caution in renal impairment",
          "May worsen psychiatric disorders",
          "Weakness (may unmask when spasticity reduced)"
        ],
        "drugInteractions": [
          {"drug": "CNS depressants", "severity": "moderate", "effect": "Additive sedation"},
          {"drug": "Alcohol", "severity": "moderate", "effect": "Additive CNS depression"},
          {"drug": "Antihypertensives", "severity": "low", "effect": "Additive hypotension"}
        ],
        "pregnancyCategory": "C",
        "lactation": "Caution - excreted in milk"
      },
      "renalAdjustment": {
        "required": true,
        "tiers": [
          {"gfr": "≥60", "adjustment": "No adjustment needed"},
          {"gfr": "30-59", "adjustment": "Use with caution; may need dose reduction"},
          {"gfr": "<30", "adjustment": "Reduce dose significantly; accumulates"}
        ]
      },
      "hepaticAdjustment": {
        "required": false,
        "notes": "No adjustment needed - renally eliminated"
      },
      "monitoring": {
        "baseline": ["Renal function"],
        "ongoing": ["Spasticity control", "Sedation", "Signs of withdrawal if dose changed"],
        "frequency": "Clinical assessment at each visit"
      },
      "patientCounseling": [
        "NEVER stop taking suddenly - can cause seizures and hallucinations",
        "Report increased weakness, sedation, or dizziness",
        "May impair driving - avoid until effects known",
        "Avoid alcohol",
        "Always have a supply - do not run out"
      ]
    }
  }
}
